Faculty Opinions recommendation of Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717969433.793480577 ◽

2013 ◽

Author(s):

Nancy Lin ◽

Ines Vaz-Luis

Keyword(s):

Breast Cancer ◽

Early Stage ◽

Her2 Positive ◽

Phase 3 ◽

Her2 Positive Breast Cancer ◽

Randomised Controlled ◽

Positive Breast Cancer

Download Full-text

Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(12)70508-9 ◽

2013 ◽

Vol 14 (1) ◽

pp. 88-96 ◽

Author(s):

Paul E Goss ◽

Ian E Smith ◽

Joyce O'Shaughnessy ◽

Bent Ejlertsen ◽

Manfred Kaufmann ◽

...

Keyword(s):

Breast Cancer ◽

Early Stage ◽

Her2 Positive ◽

Phase 3 ◽

Her2 Positive Breast Cancer ◽

Randomised Controlled ◽

Positive Breast Cancer

Download Full-text

Faculty Opinions recommendation of Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718178616.793487310 ◽

2013 ◽

Author(s):

Ana Maria Gonzalez-Angulo

Keyword(s):

Breast Cancer ◽

Neoadjuvant Treatment ◽

Her2 Positive ◽

Phase 3 ◽

Her2 Positive Breast Cancer ◽

Randomised Controlled ◽

Positive Breast Cancer

Download Full-text

Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(13)70502-3 ◽

2013 ◽

Vol 14 (13) ◽

pp. 1317-1325 ◽

Author(s):

Aman U Buzdar ◽

Vera J Suman ◽

Funda Meric-Bernstam ◽

A Marilyn Leitch ◽

Matthew J Ellis ◽

...

Keyword(s):

Breast Cancer ◽

Neoadjuvant Treatment ◽

Her2 Positive ◽

Phase 3 ◽

Her2 Positive Breast Cancer ◽

Randomised Controlled ◽

Positive Breast Cancer

Download Full-text

FDA approves neratinib for extended adjuvant treatment of early stage HER2-positive breast cancer

Case Medical Research ◽

10.31525/fda1-ucm567259.htm ◽

2017 ◽

Author(s):

Keyword(s):

Breast Cancer ◽

Adjuvant Treatment ◽

Early Stage ◽

Her2 Positive ◽

Her2 Positive Breast Cancer ◽

Positive Breast Cancer

Download Full-text

Faculty Opinions recommendation of 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718043513.793482079 ◽

2013 ◽

Author(s):

Ana Maria Gonzalez-Angulo

Keyword(s):

Breast Cancer ◽

Randomised Controlled Trial ◽

Controlled Trial ◽

Her2 Positive ◽

Adjuvant Trastuzumab ◽

Her2 Positive Breast Cancer ◽

Randomised Controlled ◽

Positive Breast Cancer

Download Full-text

Trastuzumab emtansine (T-DM1) versus trastuzumab in Chinese patients with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy for HER2-positive breast cancer in the phase 3 KATHERINE study

Breast Cancer Research and Treatment ◽

10.1007/s10549-021-06166-y ◽

2021 ◽

Author(s):

Chiun-Sheng Huang ◽

Youngsen Yang ◽

Ava Kwong ◽

Shin-Cheh Chen ◽

Ling-Ming Tseng ◽

...

Keyword(s):

Breast Cancer ◽

Targeted Therapy ◽

Neoadjuvant Chemotherapy ◽

Invasive Disease ◽

Chinese Patients ◽

Trastuzumab Emtansine ◽

Her2 Positive ◽

Phase 3 ◽

Her2 Positive Breast Cancer ◽

Positive Breast Cancer

Download Full-text

Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials

The Lancet Oncology ◽

10.1016/s1470-2045(21)00288-6 ◽

2021 ◽

Vol 22 (8) ◽

pp. 1139-1150

Author(s):

Rosie Bradley ◽

Jeremy Braybrooke ◽

Richard Gray ◽

Robert Hills ◽

Zulian Liu ◽

...

Keyword(s):

Breast Cancer ◽

Early Stage ◽

Meta Analysis ◽

Randomised Trials ◽

Her2 Positive ◽

Her2 Positive Breast Cancer ◽

Positive Breast Cancer

Download Full-text

Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(18)30570-9 ◽

2018 ◽

Vol 19 (12) ◽

pp. 1630-1640 ◽

Author(s):

Mette S van Ramshorst ◽

Anna van der Voort ◽

Erik D van Werkhoven ◽

Ingrid A Mandjes ◽

Inge Kemper ◽

...

Keyword(s):

Breast Cancer ◽

Neoadjuvant Chemotherapy ◽

Her2 Positive ◽

Phase 3 ◽

Her2 Positive Breast Cancer ◽

Positive Breast Cancer

Download Full-text

Impact of timing of trastuzumab initiation on long-term outcome of patients with early-stage HER2-positive breast cancer: the “one thousand HER2 patients” project

British Journal of Cancer ◽

10.1038/s41416-018-0114-x ◽

2018 ◽

Vol 119 (3) ◽

pp. 374-380 ◽

Author(s):

Giuseppe Gullo ◽

Naomi Walsh ◽

David Fennelly ◽

Reetesh Bose ◽

Janice Walshe ◽

...

Keyword(s):

Breast Cancer ◽

Early Stage ◽

Her2 Positive ◽

Term Outcome ◽

Long Term Outcome ◽

Her2 Positive Breast Cancer ◽

The One ◽

Positive Breast Cancer

Download Full-text

Adjuvant breast cancer: (neo)adjuvant therapy for HER2-positive breast cancer

memo - Magazine of European Medical Oncology ◽

10.1007/s12254-019-00530-x ◽

2019 ◽

Vol 12 (4) ◽

pp. 312-314 ◽

Author(s):

Christoph Suppan ◽

Marija Balic

Keyword(s):

Breast Cancer ◽

Adjuvant Therapy ◽

Annual Meeting ◽

Early Stage ◽

Postoperative Treatment ◽

Her2 Positive ◽

Her2 Positive Breast Cancer ◽

Adjuvant Breast Cancer ◽

American Society ◽

Positive Breast Cancer

Summary Early stage HER2-positive cancer outcomes have been substantially improved over the last two decades, but there is still some potential for improvement. Several studies on the preoperative/postoperative treatment of HER2-positive breast cancer were presented at the American Society of Clinical Oncology (ASCO) 2019 annual meeting.

Download Full-text